Momelotinib dihydrochloride is under clinical development by GSK and currently in Pre-Registration for Myelofibrosis. According to GlobalData, Pre-Registration drugs for Myelofibrosis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Momelotinib dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Momelotinib dihydrochloride overview
Momelotinib (CYT-387) is under development for the treatment of primary myelofibrosis (PMF), secondary myelofibrosis, polycythemia vera myelofibrosis (PPV-MF), thrombocythaemia myelofibrosis. It is administered orally. It is Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor. It was also under development for the treatment of metastatic pancreatic ductal adenocarcinoma, metastatic non-small cell lung cancer, post-polycythemia vera (PV) and essential thrombocythemia.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
For a complete picture of Momelotinib dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.